Loading...
XNASANIK
Market cap237mUSD
Jan 16, Last price  
16.19USD
1D
1.06%
1Q
-35.40%
Jan 2017
-66.93%
Name

Anika Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:ANIK chart
P/E
—
P/S
1.42
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-0.04%
Rev. gr., 5y
9.56%
Revenues
167m
+6.67%
26,466,00029,835,00026,840,61430,829,82135,779,78740,135,70455,556,59464,778,63571,358,50575,081,154105,594,83992,999,000103,379,000113,420,000105,555,000114,610,000130,457,000147,794,000156,236,000166,662,000
Net income
-83m
L+456.34%
11,190,0005,893,0004,604,2166,035,2543,629,1953,687,5674,315,9958,466,68011,757,46020,574,52138,319,47930,758,00032,547,00031,816,00018,722,00027,193,000-23,982,0004,134,000-14,859,000-82,667,000
CFO
-2m
L
23,824,0006,452,0002,001,1724,492,6423,407,2313,094,7057,853,46110,173,13410,548,67725,165,00139,978,37539,064,00023,801,00040,812,00034,918,00037,005,00013,065,0008,397,0004,409,000-1,788,000
Earnings
Mar 11, 2025

Profile

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
URL
https://anika.com/
IPO date
May 16, 1985
Employees
345
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
166,662
6.67%
156,236
5.71%
Cost of revenue
96,264
90,842
Unusual Expense (Income)
NOPBT
70,398
65,394
NOPBT Margin
42.24%
41.86%
Operating Taxes
(2,660)
(3,887)
Tax Rate
NOPAT
73,058
69,281
Net income
(82,667)
456.34%
(14,859)
-459.43%
Dividends
Dividend yield
Proceeds from repurchase of equity
(5,000)
(253)
BB yield
1.51%
0.06%
Debt
Debt current
2,133
2,073
Long-term debt
55,941
57,634
Deferred revenue
Other long-term liabilities
404
398
Net debt
(14,793)
(26,620)
Cash flow
Cash from operating activities
(1,788)
4,409
CAPEX
(5,427)
(7,486)
Cash from investing activities
(5,427)
(7,486)
Cash from financing activities
(6,324)
(4,852)
FCF
71,691
47,547
Balance
Cash
72,867
86,327
Long term investments
Excess cash
64,534
78,515
Stockholders' equity
122,256
204,422
Invested Capital
177,172
237,526
ROIC
35.23%
29.01%
ROCE
29.13%
20.28%
EV
Common stock shares outstanding
14,656
14,561
Price
22.66
-23.45%
29.60
-17.39%
Market cap
332,105
-22.95%
431,006
-17.80%
EV
317,312
404,386
EBITDA
84,615
79,881
EV/EBITDA
3.75
5.06
Interest
654
Interest/NOPBT
1.00%